Publication date: Jun 09, 2019
In Parkinson’s disease (PD), the course of the disorder is highly variable between patients. Well-designed, prospective studies for identifying PD progression biomarkers are necessary. Our aim is to show the results of baseline evaluations of an ongoing global PD Project, COPPADIS-2015 (COhort of Patient’s with PArkinson’s DIsease in Spain, 2015).
Observational, descriptive, nationwide study (Spain). The recruitment period ended in October 2017. Baseline evaluation included more than 15 validated scales and complementary studies in a subgroup of participants.
1,174 subjects from 35 centers were considered valid for baseline analysis: 694 patients (62.6 +/- 8.9 years old, 60.3% males), 273 caregivers (58.5 +/- 11.9 years old, 31.8% males), and 207 controls (61 +/- 8.3 years old, 49.5% males). The mean disease duration was 5.5 +/- 4.4 years. Hoehn&Yahr stage was 1 or 2 in 90.7% of the patients while 33.9% and 18.1% of them presented motor fluctuations and dyskinesias, respectively. Mean Non-Motor Symptoms Scale (NMSS) total score was 45.4 +/- 38.1, and 30.4% of the patients presented cognitive impairment, 16.1% major depression, 12.7% impulse control disorder and 7.2% compulsive behaviour, 57.2% pain, and 13.2% falls. Compared to the control group, PD patients presented a significantly higher burden of non-motor symptoms and a worse quality of life. More than 300 subjects conducted complementary studies (serum biomarkers, genetic and neuroimaging).
PD is a complex disorder and different NMS are frequently present and are more prevalent than in controls. In real clinical practice is important to ask for them. This article is protected by copyright. All rights reserved.
|disease||DOID||impulse control disorder|